A comprehensive view of Merck & Co. Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

European Commission approves Merck’s KEYTRUDA pembrolizumab plus chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults

Merck & Co. Inc. Announces FDA Approval for Pulmonary Arterial Hypertension Treatment, Reinforcing Commitment to PAH Patients and Advancing Clinical Trial Diversity

Merck's second trial testing Lynparza with Keytruda to treat metastatic non-small cell lung cancer fails to show significant improvement on life expectancy or disease progression; Merck remains committed to exploring Keytruda combinations in lung cancer

Merck announces plans to develop a new multi-valent HPV vaccine offering broader protection against multiple HPV types; the company will also initiate clinical trials to test the efficacy and safety of a single-dose regimen of Gardasil 9

GlobalData expects GLP-1 drugs like Novo Nordisk's Ozempic to become bestselling drug class in 2024, dethroning PD-1 inhibitors like Merck's Keytruda; GLP-1 drugs' expected annual sales of US$50B marks shift in demand from oncology to metabolic disorders

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count